Clarus Therapeutics Adds $8 Million

Clarus Therapeutics Inc., a Northbrook, Ill.-based developer of an oral testosterone replacement product, has raised $8 million in Series C funding. H.I.G. Ventures led the round, and was joined by return backer Thomas, McNerney & Partners. The company has now raised over $12 million in total funding.

PRESS RELEASE
Clarus Therapeutics, Inc., a private firm focused on the development of an oral testosterone replacement product, today announced the close of an $8 million Series C financing. H.I.G. Ventures led the round and was joined by Thomas, McNerney & Partners